<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79033">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037646</url>
  </required_header>
  <id_info>
    <org_study_id>926.24</org_study_id>
    <nct_id>NCT02037646</nct_id>
  </id_info>
  <brief_title>Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral</brief_title>
  <official_title>Evaluating the Effectiveness of Screening Strategies Using Quantitative Versus Qualitative Fecal Immunochemical Test (FIT) to Prioritize Urgency of Colonoscopy Referral - a Randomized Controlled Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <authority>Malaysia: National Medical Research Register</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to determine whether there is a difference in time to
      diagnosis of advanced colorectal neoplasms using quantitative Fecal Immunochemical Tests
      (FIT) to prioritize referral for colonoscopy (intervention) compared to usual care
      (qualitative FIT and appointment-based referral).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that quantitative FIT will enable faster detection of advanced neoplasms
      compared to qualitative FIT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Time to diagnosis of advanced colorectal neoplasms</measure>
    <time_frame>40-90 days from the time of enrolment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of screening costs</measure>
    <time_frame>Up to 90 days following enrolment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient anxiety levels</measure>
    <time_frame>Up to 90 days after enrolment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction scores</measure>
    <time_frame>Up to 90 days after enrolment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:
&gt;200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list &lt;100 ng/dL - no colonoscopy
Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:
Positive - colonoscopy as per waiting list Negative - no colonoscopy
Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Qualitative fecal immunochemical test</intervention_name>
    <description>This test measures the amount of blood within the submitted stool specimen</description>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quantitative fecal immunochemical test</intervention_name>
    <description>This test detects presence or absence of blood within a submitted stool specimen.</description>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.</description>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cost analysis</intervention_name>
    <description>Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.</description>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anxiety scores</intervention_name>
    <description>Hospital Anxiety and Depression Scale (HADS) questionnaire</description>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient satisfaction scores</intervention_name>
    <description>A 5-point patient satisfaction score will be documented at each patient visit related to screening.</description>
    <arm_group_label>Qualitative fecal immunochemical test</arm_group_label>
    <arm_group_label>Quantitative fecal immunochemical test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 50 years and above

        Exclusion Criteria:

          -  Lower gastrointestinal tract symptoms such as diarrhoea, constipation, per rectal
             bleeding

          -  Personal history of colorectal tumour or cancer

          -  Family history of familial adenomatous polyposis or hereditary non-polyposis
             colorectal cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>April C Roslani, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April C Roslani, MBBCh</last_name>
    <email>april@ummc.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chirk-Jenn Ng, MBBS</last_name>
    <email>ngcj@ummc.edu.my</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>April C Roslani, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chirk-Jenn Ng, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Screening</keyword>
  <keyword>Fecal occult blood</keyword>
  <keyword>Fecal immunochemical test</keyword>
  <keyword>Qualitative</keyword>
  <keyword>Quantitative</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
